Xin Lang Cai Jing·2026-01-05 04:03Market Overview - The Hong Kong stock market indices experienced fluctuations and slight declines, with the Hang Seng Index down by 0.08% to 26,316.55 points, the Hang Seng Tech Index down by 0.18%, and the State-Owned Enterprises Index down by 0.19% [1][9]. Technology Sector - In the tech sector, Kuaishou surged over 9%, and Bilibili rose more than 5%, while Xiaomi and NetEase fell over 2% [1][9]. Biopharmaceutical Sector - The biopharmaceutical stocks led the gains, with Huadong Medicine rising by 7%. The National Medical Products Administration announced that 76 innovative drugs are expected to be approved in China by 2025, significantly surpassing the 48 approved in 2024, marking a historical high [2][11]. Real Estate Sector - Real estate stocks strengthened, with Shimao Group increasing by over 9%. An article in "Qiushi" magazine emphasized the critical role of real estate in the national economy and the need for proactive measures to stabilize market expectations [5][13]. Brain-Computer Interface Sector - The brain-computer interface concept saw significant gains, with Nanjing Panda Electronics rising over 44%. Elon Musk's Neuralink announced plans for large-scale production of brain interface devices starting in 2026, aiming to streamline surgical processes and reduce invasiveness [6][14]. Oil Sector - Oil stocks weakened, with PetroChina declining over 4%. The U.S. has initiated military actions against Venezuela, with plans for major oil companies to invest billions in repairing the country's oil infrastructure while maintaining an effective oil embargo [7][15].